Gainers

• Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million.
• uniQure (NASDAQ:QURE) shares increased by 9.5% to $46.2. The company's market cap stands at $2.7 billion. As per the press release, Q2 earnings came out yesterday.
• Guardant Health (NASDAQ:GH) shares moved upwards by 8.3% to $165.0. The market value of their outstanding shares is at $19.1 billion. As per the press release, Q2 earnings came out today.
• CareDx (NASDAQ:CDNA) shares increased by 7.61% to $41.0. The company's market cap stands at $1.8 billion. The company's, Q2 earnings came out today.
• Castle Biosciences (NASDAQ:CSTL) shares moved upwards by 7.61% to $28.83. The company's market cap stands at $741.0 million. As per the news, the Q2 earnings report came out today.
• Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 7.42% to $1.23. The company's market cap stands at $3.1 million.

Losers

• Karyopharm Therapeutics (NASDAQ:KPTI) stock fell 59.1% to $2.87 during Thursday's after-market session. The company's market cap stands at $155.4 million.
• Myriad Genetics (NASDAQ:MYGN) shares fell 30.57% to $3.73. The market value of their outstanding shares is at $476.0 million. As per the press release, Q2 earnings came out today.
• Nuwellis (NASDAQ:NUWE) shares decreased by 28.98% to $3.16.
• Fulgent Genetics (NASDAQ:FLGT) shares decreased by 16.87% to $16.8. The market value of their outstanding shares is at $607.1 million. As per the news, the Q2 earnings report came out today.
• Alignment Healthcare (NASDAQ:ALHC) stock decreased by 14.3% to $15.95. The company's market cap stands at $3.7 billion. The company's, Q2 earnings came out today.
• Cerus (NASDAQ:CERS) stock decreased by 13.85% to $2.49. The market value of their outstanding shares is at $575.0 million. As per the press release, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.